NeoPhore Ltd Employee Directory
Biotechnology ResearchEngland, United Kingdom11-50 Employees
NeoPhore Ltd is a London-based biotechnology research company focused on cancer immunotherapy. The company aims to broaden access to disease-transforming immunotherapy by transiently inhibiting DNA Mismatch Repair to replicate the strong responses seen in patients with MMR-deficient tumors. Its work seeks to extend the proven benefits of immunotherapy to more cancer patients, operating within the oncology research space with a compact team. Its intended customers are cancer patients seeking new treatment options and the clinical researchers and clinicians advancing immuno-oncology. In April 2026, NeoPhore published findings in AACR Cancer Discovery on PMS2 inhibition inducing MMR deficiency and enhancing responses to immune checkpoint blockade, a development highlighted alongside a keynote by co-founder Prof. Alberto Bardelli at the 2026 AACR Annual Meeting.